Phase II study of interferon gamma in malignant carcinoid tumors (E9292): A trial of the eastern cooperative oncology group

Investigational New Drugs

Volumn 22, Issue 1, 2004, Pages 75-81

  Stuart, Keith ^a   Levy, Donna E ^b   Anderson, Tom ^c   Axiotis, Constantine A ^d   Dutcher, Janice P ^e   Eisenberg, Andrew ^f   Erban, John K ^g   Benson III, Al Bowen ^h  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Billings Oncology Associates   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

^e OUR LADY OF MERCY MEDICAL CENTER   (United States)

^f ST JOSEPH MERCY HOSPITAL   (United States)

^g TUFTS MEDICAL CENTER   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Carcinoid; Interferon

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC AGENT; GAMMA INTERFERON;

ADULT; AGED; ALLERGY; ALOPECIA; ANEMIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER GROWTH; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HEART DISEASE; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG DISEASE; MALE; METABOLIC DISORDER; METASTASIS; MOTOR NEURON DISEASE; NAUSEA; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; MALE; MALIGNANT CARCINOID SYNDROME; MIDDLE AGED; NEOPLASM METASTASIS; SURVIVAL RATE;

EID: 1042268180     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000006177.46798.1f     Document Type: Article

References (37)

1. Modlin IM, Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer 79(4): 813-829, 1997
2. Creutzfeldt W, Stockmann F: Carcinoids and carcinoid syndrome. Am J Med 82(5B): 4-16, 1987
3. Kulke MH, Mayer RJ: Carcinoid tumors. N Engl J Med 340(11): 858-868, 1999
4. Moertel CG: Karnofsky memorial lecture. An odyssey in the land of small tumors. J Clin Oncol 5(10): 1502-1522
5. Creutzfeldt W: Historical background and natural history of carcinoids. Digestion 55(3): 3-10, 1994
6. Perry LJ et al.: Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116(6): 1111-1116; discussion 1116-1117, 1994
7. Oberg K et al.: Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat Rep 70(11): 1297-1304, 1986
8. Carlin JM et al.: Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures. J Immunol 139(7): 2414-2418, 1987
9. Markman M: Models for the antitumor action of interferon against human ovarian cancer. Annual Meeting of the International Society for Interferon Research, 1991
10. Ozaki Y, Edelstein MP, Duch DS: Induction of indoleamine 2,3-dioxygenase: A mechanism of the antitumor activity of interferon gamma. Proc Natl Acad Sci USA 85(4): 1242-1246, 1988
11. de la Maza LM, Peterson EM: Dependence of the in vitro antiproliferative activity of recombinant human gamma-interferon on the concentration of tryptophan in culture media. Cancer Res 48(2): 346-350, 1988
12. Takikawa O et al.: Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem 263(4): 2041-2048, 1988
13. WHO Handbook for Reporting Results of Cancer Treatment. Geneva (Switzerland): World Health Organization Offset Publication No. 48; 1979
14. Kaplan EL: Nonparametric estimation of incomplete observations. J Amer Statist Assoc 53: 457-481, 1958
15. Oberg K, Eriksson B: The role of interferons in the management of carcinoid tumours. Br J Haematol 79(1): 74-77, 1991
16. Oberg K: Carcinoid tumors: Current Concepts in Diagnosis and Treatment. Oncologist 3(5): 339-345, 1998
17. Dirix LY et al.: Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors - an antiangiogenic effect? Anti-Cancer Drugs 7(2): 175-181, 1996
18. Di Bartolomeo M et al.: Treatment of carcinoid syndrome with recombinant interferon alpha-2a. Acta Oncol 32(2): 235-238, 1993
19. Joensuu H, Kumpulainen E, Grohn P: Treatment of metastatic carcinoid tumour with recombinant interferon alfa. Eur J Cancer 28A(10): 1650-1653
20. Valimaki M et al.: Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer. 67(3): 547-549, 1991
21. Janson ET, Kauppinen HL, Oberg K: Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial. Acta Oncol 32(2): 231-233, 1993
22. di Bartolomeo M, et al.: Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 77(2): 402-8, 1996
23. Joensuu H, Katka K, Kujari H: Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide. Acta Endocrinol (Copenh) 126(2): 184-185, 1992
24. Janson ET, Oberg K: Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon. Acta Oncol 32(2): 225-229, 1993
25. van Hazel GA, Rubin J, Moertel CG: Treatment of metastatic carcinoid tumor with dactinomycin or dacarbazine. Cancer Treat Rep 67(6): 583-585, 1983
26. Engstrom PF et al.: Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 2(11): 1255-1259, 1984
27. Feldman JM et al.: Streptozotocin treatment of metastatic carcinoid tumors. South Med J 65(11): 1325-1327, 1972
28. Iweze FI, Owen-Smith M, Polak J: Carcinoid syndrome treated with streptozotocin. Proc R Soc Med 65(2): 164-165, 1972
29. Moertel CG: Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J Clin Oncol 1(11): 727-740, 1983
30. Moertel CG, Rubin J, O'Connell MJ: Phase II study of cisplatin therapy in patients with metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Treat Rep 70(12): 1459-1460, 1986
31. Bukowski RM et al.: Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 73(5): 1505-1508, 1994
32. Bukowski RM et al.: A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 60(12): 2891-2895, 1987
33. Chernicoff D et al.: Combination chemotherapy for islet cell carcinoma and metastatic carcinoid tumors with 5-fluorouracil and streptozotocin. Cancer Treat Rep 63(5): 795-796, 1979
34. Moertel CG, Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2(4): 327-334, 1979
35. Ridolfi R et al.: Chemotherapy with 5-fluorouracil and streptozotocin in carcinoid tumors of gastrointestinal origin: Experiences with 13 patients. J Chemother 3(5): 328-331, 1991
36. Andreyev HJ et al.: Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol 13(6): 1486-1492, 1995
37. Quaedvlieg PF et al.: Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients. Ann Oncol 12(9): 1295-1300, 2001